Skip to main content

Peer Review reports

From: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

Original Submission
26 Apr 2017 Submitted Original manuscript
6 Jun 2017 Reviewed Reviewer Report - Brain Bressler
13 Jun 2017 Reviewed Reviewer Report - Karmiris Konstantinos
23 Jun 2017 Reviewed Reviewer Report - Thomas Van Stappen
27 Jun 2017 Author responded Author comments - Lorant Gonczi
Resubmission - Version 2
27 Jun 2017 Submitted Manuscript version 2
1 Jul 2017 Reviewed Reviewer Report - Karmiris Konstantinos
5 Jul 2017 Author responded Author comments - Lorant Gonczi
Resubmission - Version 3
5 Jul 2017 Submitted Manuscript version 3
18 Jul 2017 Author responded Author comments - Lorant Gonczi
Resubmission - Version 4
18 Jul 2017 Submitted Manuscript version 4
Publishing
31 Jul 2017 Editorially accepted
8 Aug 2017 Article published 10.1186/s12876-017-0654-1

You can find further information about peer review here.

Back to article page